Analysis of Secondary Leukemia and Myelodysplastic Syndrome After Chemotherapy for Solid Organ Tumors Using the Food and Drug Administration Adverse Event Reporting System (FAERS)

Analysis of Secondary Leukemia and Myelodysplastic Syndrome After Chemotherapy for Solid Organ Tumors Using the Food and Drug Administration Adverse Event Reporting System (FAERS)

Purpose: As the prognosis of cancer patients deteriorates, secondary carcinogenesis after chemotherapy, especially secondary hematological malignancies, becomes a serious problem. However, information on the frequency and time of onset of secondary hematological malignancies and the risk of hematol...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Takehiro Kawashiri, Daisuke Kobayashi, Mayako Uchida, Shiori Hiromoto, Masashi Inoue, Hajime Ikeda, Mizuki Inoue, Takao Shimazoe
Formato: article
Lenguaje:EN
Publicado: Canadian Society for Pharmaceutical Sciences 2021
Materias:
Therapeutics. Pharmacology
RM1-950
Pharmacy and materia medica
RS1-441
Acceso en línea:https://doaj.org/article/cc3f6b3c7d0942a7bbb6d685e86a87c2
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares